Clinical outcomes and predictors of delayed echocardiographic response to cardiac resynchronization therapy
Naoki Tsurumi1, Yasuya Inden1, Satoshi Yanagisawa1
1Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Insights
Delayed response to cardiac resynchronization therapy (CRT) has similar outcomes to early response. Factors like longer heart failure history and suboptimal LV lead placement predict delayed CRT response.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Management
Background:
- Clinical outcomes and mechanisms of delayed responses to cardiac resynchronization therapy (CRT) are not well understood.
- Investigating early versus delayed CRT response is crucial for optimizing patient management.
Purpose of the Study:
- To investigate differences in clinical outcomes between early and delayed responders to CRT.
- To gain insight into the mechanisms underlying early and delayed responses to CRT.
Main Methods:
- Retrospective study of 110 patients undergoing CRT implantation.
- Response defined by ≥15% reduction in left ventricular (LV) end-systolic volume at 1 and 3 years.
- Latest mechanical activation site (LMAS) identified using 2D speckle-tracking radial strain analysis.
Main Results:
- 71% of patients showed an early response at 1 year.
- Of early non-responders, 38% became delayed responders by 3 years.
- Delayed and early responders had similar long-term prognosis; non-responders had worse outcomes.
Conclusions:
- Prognosis after CRT is similar regardless of response timing (early vs. delayed).
- Delayed CRT response is associated with longer heart failure duration, suboptimal LV lead placement, and shorter pre-QRS duration.
Introduction:
The clinical outcomes and mechanisms of delayed responses to cardiac resynchronization therapy (CRT) remain unclear. We aimed to investigate the differences in outcomes and gain insight into the mechanisms of early and delayed responses to CRT.
Methods:
This retrospective study included 110 patients who underwent CRT implantation. Positive response to CRT was defined as ≥15% reduction of left ventricular (LV) end-systolic volume on echocardiography at 1 year (early phase) and 3 years (delayed phase) after implantation. The latest mechanical activation site (LMAS) of the LV was identified using two-dimensional speckle-tracking radial strain analysis.
Results:
Seventy-eight (71%) patients exhibited an early response 1 year after CRT implantation. Of 32 non-responders in the early phase, 12 (38%) demonstrated a delayed response, and 20 (62%) were classified as non-responders after 3 years. During the follow-up time of 10.3 ± 0.5 years, the delayed and early responders had a similar prognosis of mortality and heart failure (HF) hospitalization. In contrast, non-responders had a worse prognosis. Multivariate analysis revealed that a longer duration (months) between initial HF hospitalization and CRT (odds ratio [OR]: 1.126; 95% confidence interval [CI]: 1.036-1.222; p = .005), non-exact concordance of LV lead location with LMAS (OR: 32.744; 95% CI: 1.101-973.518; p = .044), and pre-QRS duration (OR: 0.901; 95% CI: 0.827-0.981; p = .016) were independent predictors of delayed response to CRT compared with early response.
Conclusion:
The prognoses were similar regardless of the response time after CRT. A longer history of HF, suboptimal LV lead position, and shorter pre-QRS duration were related to delayed response than early response.
More Related Videos
10:17Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
08:19Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs
Published on: July 12, 2022
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy
Heart Failure VI: Adjunct Therapies
Cardiomyopathy III: Hypertrophic Cardiomyopathy
